Contineum Therapeutics Inc (CTNM)

$13.34 -0.31 (-2.27%)
Market Cap 498.06M
Revenue (ttm) 0.00
Net Income (ttm) -59.98M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 168,800
Avg Vol 291,924
Day's Range N/A - N/A
Shares Out 37.34M
Stochastic %K 64%
Beta 1.07
Analysts Strong Sell
Price Target $22.00

Company Profile

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. It also develops PIPE-30...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 333 5280
Address:
3565 General Atomics Court, Suite 200, San Diego, United States
gata2016
gata2016 Mar. 25 at 2:01 PM
$CABA Im trying to tell you. Good news it right around the corner. Better get in at a premium! $CTNM $IBRX $TERN
0 · Reply
gata2016
gata2016 Mar. 23 at 7:42 PM
$CABA Book it. "Yes, it is highly likely—almost standard practice—for a biotechnology company to schedule a conference call, webcast, or investor event to release positive clinical trial data. In RESET-MG, data will be presented in an oral presentation at 1:24 p.m. CDT on Monday, April 20, 2026" $CTNM $SANA $ADVM
4 · Reply
OwenLambert
OwenLambert Mar. 19 at 6:47 PM
$CTNM biotech setup with real asymmetry and the move only matters if buyers keep pressing the ask
0 · Reply
char13
char13 Mar. 17 at 9:43 AM
Good morning. Early movers premarket $WNM.X 28m play which sells food in China $CTNM 500m biopharma play $JVA 20m market cap and operating in the coffee industry
0 · Reply
focafoca99
focafoca99 Mar. 4 at 12:20 AM
$CTNM has an upcoming investor stage... will they drop enough color to wake up this stock?
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 26 at 3:24 PM
$CTNM Current Stock Price: $15.76 Contracts to trade: $15.0 CTNM Mar 20 2026 Call Entry: $0.30 Exit: $0.53 ROI: 77% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 17 at 8:57 PM
$CTNM RSI: 55.51, MACD: 0.8291 Vol: 1.10, MA20: 14.21, MA50: 12.50 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
gata2016
gata2016 Feb. 12 at 3:01 PM
$CABA loved what I just heard a good data coming in! $CTNM $KYTX don't miss the boat on this.
1 · Reply
ClayClymer689
ClayClymer689 Feb. 11 at 3:35 PM
$CTNM Contineum Therapeutics; biotech focused on neuroscience and inflammation; early-stage pipeline; binary clinical catalysts ahead.
0 · Reply
kaoz
kaoz Feb. 11 at 3:04 PM
$CTNM failed primary. Yikes. Someone’s pumping so big boys can dump on retail.
0 · Reply
Latest News on CTNM
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 13, 2026, 4:05 PM EDT - 16 days ago

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

Mar 5, 2026, 4:05 PM EST - 24 days ago

Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference

Mar 3, 2026, 4:05 PM EST - 26 days ago

Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference

Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering

Dec 11, 2025, 10:24 PM EST - 3 months ago

Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering

Contineum Therapeutics Announces Proposed $75.0 Million Public Offering

Dec 11, 2025, 4:05 PM EST - 3 months ago

Contineum Therapeutics Announces Proposed $75.0 Million Public Offering

Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference

Nov 24, 2025, 4:05 PM EST - 4 months ago

Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference

Contineum Therapeutics' Multiple Sclerosis Trial Disappoints, But Analyst Sees Other Assets Driving Value

Nov 21, 2025, 11:49 AM EST - 4 months ago

Contineum Therapeutics' Multiple Sclerosis Trial Disappoints, But Analyst Sees Other Assets Driving Value

Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

Nov 20, 2025, 4:05 PM EST - 4 months ago

Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

Oct 30, 2025, 4:05 PM EDT - 5 months ago

Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Sep 18, 2025, 8:05 AM EDT - 6 months ago

Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Contineum Therapeutics to Present at September Investor Conferences

Aug 28, 2025, 4:05 PM EDT - 7 months ago

Contineum Therapeutics to Present at September Investor Conferences

Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones

Aug 5, 2025, 4:05 PM EDT - 8 months ago

Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones

Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Jun 25, 2025, 8:15 AM EDT - 9 months ago

Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 15, 2025, 4:05 PM EDT - 11 months ago

Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference

Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

May 14, 2025, 4:05 PM EDT - 11 months ago

Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

Apr 28, 2025, 4:05 PM EDT - 11 months ago

Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

Mar 17, 2025, 4:05 PM EDT - 1 year ago

Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum

Mar 12, 2025, 4:05 PM EDT - 1 year ago

Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum

Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones

Mar 6, 2025, 4:05 PM EST - 1 year ago

Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791

Mar 4, 2025, 4:05 PM EST - 1 year ago

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791

Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference

Mar 3, 2025, 4:05 PM EST - 1 year ago

Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference

Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

Jan 8, 2025, 4:05 PM EST - 1 year ago

Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Dec 16, 2024, 4:05 PM EST - 1 year ago

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference

Nov 25, 2024, 8:05 AM EST - 1 year ago

Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain

Nov 18, 2024, 8:05 AM EST - 1 year ago

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain

Contineum Therapeutics to Attend Upcoming Investor Conferences

Nov 13, 2024, 4:05 PM EST - 1 year ago

Contineum Therapeutics to Attend Upcoming Investor Conferences

Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 6, 2024, 4:05 PM EST - 1 year ago

Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences

Aug 28, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences

Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

Jun 24, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

Contineum: LPA1R Antagonist Drug Advancement Against IPF With Proven Track Model

Jun 13, 2024, 2:03 PM EDT - 1 year ago

Contineum: LPA1R Antagonist Drug Advancement Against IPF With Proven Track Model

Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference

Jun 4, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference

Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary

Jun 3, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary

Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors

May 20, 2024, 4:05 PM EDT - 2 years ago

Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors

Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 16, 2024, 4:05 PM EDT - 2 years ago

Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

U.S. IPO Weekly Recap: April IPO Market Gets A Boost From Large Launches And New Filings

Apr 6, 2024, 5:50 AM EDT - 2 years ago

U.S. IPO Weekly Recap: April IPO Market Gets A Boost From Large Launches And New Filings

JNJ LOAR MAMO PACS RBRK ULS ZBAO

Contineum Therapeutics Announces Pricing of Initial Public Offering

Apr 4, 2024, 9:02 PM EDT - 2 years ago

Contineum Therapeutics Announces Pricing of Initial Public Offering

gata2016
gata2016 Mar. 25 at 2:01 PM
$CABA Im trying to tell you. Good news it right around the corner. Better get in at a premium! $CTNM $IBRX $TERN
0 · Reply
gata2016
gata2016 Mar. 23 at 7:42 PM
$CABA Book it. "Yes, it is highly likely—almost standard practice—for a biotechnology company to schedule a conference call, webcast, or investor event to release positive clinical trial data. In RESET-MG, data will be presented in an oral presentation at 1:24 p.m. CDT on Monday, April 20, 2026" $CTNM $SANA $ADVM
4 · Reply
OwenLambert
OwenLambert Mar. 19 at 6:47 PM
$CTNM biotech setup with real asymmetry and the move only matters if buyers keep pressing the ask
0 · Reply
char13
char13 Mar. 17 at 9:43 AM
Good morning. Early movers premarket $WNM.X 28m play which sells food in China $CTNM 500m biopharma play $JVA 20m market cap and operating in the coffee industry
0 · Reply
focafoca99
focafoca99 Mar. 4 at 12:20 AM
$CTNM has an upcoming investor stage... will they drop enough color to wake up this stock?
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 26 at 3:24 PM
$CTNM Current Stock Price: $15.76 Contracts to trade: $15.0 CTNM Mar 20 2026 Call Entry: $0.30 Exit: $0.53 ROI: 77% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 17 at 8:57 PM
$CTNM RSI: 55.51, MACD: 0.8291 Vol: 1.10, MA20: 14.21, MA50: 12.50 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
gata2016
gata2016 Feb. 12 at 3:01 PM
$CABA loved what I just heard a good data coming in! $CTNM $KYTX don't miss the boat on this.
1 · Reply
ClayClymer689
ClayClymer689 Feb. 11 at 3:35 PM
$CTNM Contineum Therapeutics; biotech focused on neuroscience and inflammation; early-stage pipeline; binary clinical catalysts ahead.
0 · Reply
kaoz
kaoz Feb. 11 at 3:04 PM
$CTNM failed primary. Yikes. Someone’s pumping so big boys can dump on retail.
0 · Reply
HODLHotshot
HODLHotshot Feb. 4 at 4:05 PM
$CTNM is a technology or media company; without specifics, analysis would focus on its business model, growth trajectory, and competitive moat.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 3 at 9:40 PM
$CTNM Current Stock Price: $15.24 Contracts to trade: $15.0 CTNM Feb 20 2026 Call Entry: $0.72 Exit: $1.15 ROI: 60% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
squiggleburp
squiggleburp Jan. 16 at 2:09 PM
$CTNM Okay dokey, another 12 percent honk to the PL…. Very small position though. I never listen to myself..
0 · Reply
squiggleburp
squiggleburp Jan. 13 at 6:07 PM
$CTNM who like squiggle dancing? I am here, have no fear…
0 · Reply
topstockalerts
topstockalerts Jan. 13 at 5:38 PM
$CTNM Big move developing as buyers pile in 😮. Price is moving with force. This is real momentum.
0 · Reply
garygb
garygb Jan. 6 at 5:23 PM
$CTNM Buying opportunity.
0 · Reply
gata2016
gata2016 Jan. 6 at 2:17 PM
$CABA For my fellow investors at $CTNM and $KYTX CABA is another in my portfolio worth a look. All three have a great deal of upside potential. Just playing the waiting game now.
0 · Reply
Arcides
Arcides Jan. 5 at 6:16 PM
Bios are pupu today. $CTNM
0 · Reply
gata2016
gata2016 Dec. 23 at 3:18 PM
$CTNM moved over to $KYTX just starting to run. Just moved over.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 16 at 2:02 AM
$CTNM Share Price: $11.58 Contract Selected: Jun 18, 2026 $10 Calls Buy Zone: $1.70 – $2.10 Target Zone: $2.76 – $3.37 Potential Upside: 53% ROI Time to Expiration: 184 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
aletz
aletz Dec. 15 at 2:24 PM
$CTNM https://www.biostockinfo.com/biotech-catalyst-ai-scanner-december-wk3/ CTNM's price action has been some what stable for several months despite a recent setback, can it change with new upcoming data?
0 · Reply